Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Absent in melanoma 2 (AIM2) is a pattern recognition receptor (PRR) that can be used as a DNA receptor to sense DNA or bacterial infection and release into the cytoplasmic dsDNA to form AIM2 inflammatory bodies, therefore promoting the secretion and maturation of inflammatory cytokines such as IL-1β and IL-18 to initiate an innate immune response or induce cell pyrokosis. Studies found that AIM2 is abnormally expressed in various tumors such as melanoma, breast cancer, prostate cancer, lung cancer, liver cancer, and colorectal cancer (CRC), in which AIM2 expression is absent in CRC and there are many gene frameshifts and missense mutations. The expression of AIM2 is related to the prognosis of patients, but the mechanism of AIM2 affecting tumors is not clear.
Biological Function of AIM2
AIM2 was originally discovered in human melanoma cell lines and was named for this name because it is deleted in melanoma cell lines and can reverse the melanoma tumor phenotype. AIM2 is a member of the HIN-200 (hematopoietic IFN-inducible nuclear protein containing a 200-amino-acid repeat) family of proteins with two typical domains, a highly helical thermoprotein domain PYD (pyrin) Domain) N-terminal and contains two adjacent oligonucleotides/oligosaccharide-binding domain OB (oligonucleotide/oligosaccharide-binding domain) C-terminus. AIM2 can interacts with other proteins containing a death domain, a death effector domain, and a caspase recruitment domain (CARD) to activate multiple protein effects. So AIM2 plays an important role in innate immunity, inflammation, cell differentiation and apoptosis, and the development of tumors.
AIM2 is primarily localized to the cytoplasm and has a specific ability to recognize antigenic signals and plays a key role in initiating an innate immune response. AIM2 protein binds to ASC (apoptosis-associated speck like protein containing a caspase recruitment domain), induces ASC dimerization, and then interacts with Pro-Cas- pase-1 to form AIM2-ASC-Pro-Caspase-1 inflammatory complex (also known as the AIM2 inflammatory corpus), which in turn activates caspase-1, cleaves pro-IL-1β and pro-IL-18, leading to the maturation and secretion of the inflammatory cytokines IL-1β and IL-18. Then it initiates an innate immune response. Caspase-1 simultaneously cleaves the substrate Gasdermine D, while the N-terminus of the latter induces cell-cause production while releasing mature IL-1β and IL18 out of the cell.
Figure 1. AIM2 induces nonclassical activation of the NLRP3 inflammasome. (Cunha, et al. 2017)
The formation and activation of inflammatory corposomes play an important role in host anti-infective immunity. According to different receptor proteins, they can be divided into NOD-like receptor family (NLR) NLRP1, NLRP3, NLRC4, NLRP6, NLRP12 and AIM2-like receptor family (ALR) such as AIM2, IFI16, pyrin inflammatory bodies, etc. AIM2 is the only member of the HIN-200 family that recognizes DNA-forming inflammatory bodies and activates Caspase-1. AIM2 also has certain limitations in the recognition of DNA. Although its recognition does not depend on the specific DNA sequence, it has certain requirements on the length of the DNA sequence. It can only be recognized by AIM2 when the DNA sequence reaches 80 bp. reaction.
AIM2 and Inflammation
AIM2 can regulate acute ionizing radiation and chemotherapy-induced colorectal inflammation. Acute ionizing radiation can induce apoptosis of a large number of proliferating cells such as bone marrow cells and gastrointestinal cells in a short period of time. Chemotherapy can also cause severe gastrointestinal toxicity, causeing an adverse inflammatory response, which affects its anti-tumor effect. When cells are damaged by acute ionizing radiation, AIM2 can form inflammatory corpuscles in the nucleus, inducing intestinal epithelial cells to stagnate. Blocking the action of AIM2 signaling, such as thalidomide or using the chemotherapeutic drug irinotecan (CPT-11) in AIM2-deficient mice, can significantly reduce drug side effects without affecting the anti-tumor effect of CPT-11. Thus, chemoradiotherapy has an important influence on the role of AIM2 in the development of inflammation.
Studies have found that AIM2 inflammatory bodies regulate intestinal balance through the IL-18/IL-22/STAT3 signaling pathway. Deletion of AIM2 leads to impaired IL-18 secretion, and decreased IL-22 binding protein (IL-22BP) in intestinal epithelial cells, which in turn causes loss of STAT3-dependent antimicrobial peptides (AMPs) Reg3 and Reg3-γ, causing intestinal homeostasis and inducing colon inflammation.
AIM2 and Tumor
AIM2 was originally found in human melanoma cells, and AIM2 mRNA was also detected in human spleen, small intestine, and peripheral blood leukocytes. Subsequent studies have found that IFN can increase the expression level of AIM2 in cells. Early studies suggest that AIM2 is a tumor suppressor that is expressed in melanoma, and its overexpression reverses the tumor phenotype of melanoma and inhibits the proliferation of fibroblasts. Although AIM2 has also been found to be highly expressed in cervical cancer, nasopharyngeal carcinoma, oral squamous cell carcinoma, and lung adenocarcinoma, AIM2 is under-represented in CRC, liver cancer, breast cancer, and prostate cancer. The frameshift and missense mutations of the AIM2 gene were also found in endometrial cancer, CRC, gastric cancer.
The study of human CRC cell HCT116 found that AIM2 can regulate cell cycle through PI3K/Akt pathway, block cell transition from G1 phase to S phase or block G2/M phase arrest, thereby inhibiting cell proliferation and promoting apoptosis. AIM2 inhibits DNA-PK activation, thereby inhibiting DNA-PK activation of Akt phosphorylation, whereas Akt inhibitor (API-2) reduces the number of polyps and tumors in AIM2-/- mice colon. Thus, AIM2 can reduce the risk of colorectal cancer (CRC) by affecting the cell proliferation and growth cycle by regulating the Akt pathway.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.